Compare HIKAL CHEMIC with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

HIKAL. vs DISHMAN PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    HIKAL. DISHMAN PHARMA HIKAL./
DISHMAN PHARMA
 
P/E (TTM) x 18.3 30.0 60.9% View Chart
P/BV x 3.1 3.3 93.8% View Chart
Dividend Yield % 0.8 0.7 126.7%  

Financials

 HIKAL.   DISHMAN PHARMA
EQUITY SHARE DATA
    HIKAL.
Mar-21
DISHMAN PHARMA
Mar-16
HIKAL./
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs204374 54.6%   
Low Rs67129 52.1%   
Sales per share (Unadj.) Rs139.5197.0 70.8%  
Earnings per share (Unadj.) Rs10.821.2 51.0%  
Cash flow per share (Unadj.) Rs17.734.7 51.0%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Avg Dividend yield %1.50.8 185.4%  
Book value per share (Unadj.) Rs75.7179.9 42.1%  
Shares outstanding (eoy) m123.3080.70 152.8%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.01.3 76.2%   
Avg P/E ratio x12.611.9 105.9%  
P/CF ratio (eoy) x7.77.3 105.7%  
Price / Book Value ratio x1.81.4 128.2%  
Dividend payout %18.59.4 196.2%   
Avg Mkt Cap Rs m16,73820,307 82.4%   
No. of employees `000NANA-   
Total wages/salary Rs m1,6435,355 30.7%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m17,20415,898 108.2%  
Other income Rs m50265 18.8%   
Total revenues Rs m17,25416,163 106.8%   
Gross profit Rs m3,2294,103 78.7%  
Depreciation Rs m8521,091 78.2%   
Interest Rs m362944 38.3%   
Profit before tax Rs m2,0642,334 88.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m733624 117.5%   
Profit after tax Rs m1,3311,710 77.9%  
Gross profit margin %18.825.8 72.7%  
Effective tax rate %35.526.7 132.9%   
Net profit margin %7.710.8 71.9%  
BALANCE SHEET DATA
Current assets Rs m9,25111,018 84.0%   
Current liabilities Rs m7,0339,517 73.9%   
Net working cap to sales %12.99.4 136.6%  
Current ratio x1.31.2 113.6%  
Inventory Days Days2657 46.1%  
Debtors Days Days1033 2,945.3%  
Net fixed assets Rs m10,90618,787 58.0%   
Share capital Rs m247161 152.8%   
"Free" reserves Rs m9,08714,354 63.3%   
Net worth Rs m9,33414,516 64.3%   
Long term debt Rs m2,6294,189 62.8%   
Total assets Rs m20,15729,805 67.6%  
Interest coverage x6.73.5 193.1%   
Debt to equity ratio x0.30.3 97.6%  
Sales to assets ratio x0.90.5 160.0%   
Return on assets %8.48.9 94.3%  
Return on equity %14.311.8 121.1%  
Return on capital %20.317.5 115.7%  
Exports to sales %68.724.9 276.1%   
Imports to sales %26.93.7 718.8%   
Exports (fob) Rs m11,8233,956 298.8%   
Imports (cif) Rs m4,623594 777.9%   
Fx inflow Rs m11,8234,952 238.8%   
Fx outflow Rs m4,623697 663.6%   
Net fx Rs m7,2004,255 169.2%   
CASH FLOW
From Operations Rs m2,2902,786 82.2%  
From Investments Rs m-1,562-1,529 102.2%  
From Financial Activity Rs m-969-941 102.9%  
Net Cashflow Rs m-240317 -76.0%  

Share Holding

Indian Promoters % 68.8 61.4 112.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.8 23.0 34.0%  
FIIs % 6.9 12.0 57.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.2 38.6 80.9%  
Shareholders   75,341 52,291 144.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare HIKAL. With:   SUN PHARMA    CIPLA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

Indian Share Markets End Flat; Tech Mahindra, IndusInd Bank & Bajaj Finance Top Losers(Closing)

Indian share markets traded in a rangebound fashion throughout the day today to end flat.

Related Views on News

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

The One Smallcap Stock I'll Recommend Now(Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

The Greatest Dividend Stock of All Time is...(Views On News)

Jun 16, 2022

Prudent investors should consider dividend aristocrats to create passive, predictable, and growing income to rely on whether the market moves up or down in these uncertain times.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

HIKAL. SHARE PRICE


Jun 30, 2022 03:29 PM

TRACK HIKAL.

COMPARE HIKAL. WITH

MARKET STATS